SuperworthPuma Biotechnology EPS PBYI
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.52
- Latest quarter, Q2 FY26
- $0.16
- +33% on a year earlier
- Fiscal year 2025
- $0.61
- +0% on the year before
Puma Biotechnology's earnings per share was $0.52 over the twelve months to Jun 30, 2026, down 47% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.16, up 33% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.61 | +0% |
| FY2024 | $0.61 | +33% |
| FY2023 | $0.46 | n/a |
| FY2022 | $0.00 | n/a |
| FY2021 | −$0.72 | n/a |
| FY2020 | −$1.52 | n/a |
| FY2019 | −$1.96 | n/a |
| FY2018 | −$2.99 | n/a |
| FY2017 | −$7.85 | n/a |
| FY2016 | −$8.30 | n/a |
| FY2015 | −$7.44 | n/a |
| FY2014 | −$4.72 | n/a |
| FY2013 | −$1.90 | n/a |
| FY2012 | −$3.44 | n/a |
| FY2011 | −$0.62 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.16 | +33% | $0.52 | |
| Q1 FY26 | −$0.07 | −217% | $0.48 | |
| Q4 FY25 | $0.26 | −33% | $0.61 | |
| Q3 FY25 | $0.17 | −59% | $0.74 | |
| Q2 FY25 | $0.12 | n/a | $0.98 | |
| Q1 FY25 | $0.06 | n/a | $0.77 | |
| Q4 FY24 | $0.39 | +50% | $0.61 | |
| Q3 FY24 | $0.41 | +242% | $0.48 | |
| Q2 FY24 | −$0.09 | −280% | $0.19 | |
| Q1 FY24 | −$0.10 | −433% | $0.33 | |
| Q4 FY23 | $0.26 | n/a | $0.46 | |
| Q3 FY23 | $0.12 | n/a | $0.08 |
Against its peers
Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ARVNArvinas | $0.16 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
Where Puma Biotechnology ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Puma Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.